Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Pooled Subject-Reported Outcomes From 2 Phase 3 Studies of OnabotulinumtoxinA for Simultaneous Treatment of Forehead and Glabellar Lines.

Ogilvie P, Rivkin AZ, Dayan S, Yoelin SG, Larsen KE, Varon S, Garcia JK.

Dermatol Surg. 2019 Sep 23. doi: 10.1097/DSS.0000000000002153. [Epub ahead of print]

PMID:
31567611
2.

Simultaneous profiling of 3D genome structure and DNA methylation in single human cells.

Lee DS, Luo C, Zhou J, Chandran S, Rivkin A, Bartlett A, Nery JR, Fitzpatrick C, O'Connor C, Dixon JR, Ecker JR.

Nat Methods. 2019 Oct;16(10):999-1006. doi: 10.1038/s41592-019-0547-z. Epub 2019 Sep 9.

3.

OnabotulinumtoxinA for Treatment of Forehead and Glabellar Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Double-Blind Study.

Ogilvie P, Rivkin AZ, Dayan S, Yoelin SG, Weichman BM, Garcia JK.

Dermatol Surg. 2019 May;45(5):689-699. doi: 10.1097/DSS.0000000000001779.

PMID:
31034447
4.

Histamine releasing factor and elongation factor 1 alpha secreted via malaria parasites extracellular vesicles promote immune evasion by inhibiting specific T cell responses.

Demarta-Gatsi C, Rivkin A, Di Bartolo V, Peronet R, Ding S, Commere PH, Guillonneau F, Bellalou J, Brûlé S, Abou Karam P, Cohen SR, Lagache T, Janse CJ, Regev-Rudzki N, Mécheri S.

Cell Microbiol. 2019 Jul;21(7):e13021. doi: 10.1111/cmi.13021. Epub 2019 Apr 1.

PMID:
30835870
5.

OnabotulinumtoxinA for Simultaneous Treatment of Upper Facial Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Study.

Rivkin AZ, Ogilvie P, Dayan S, Yoelin SG, Weichman BM, Garcia JK.

Dermatol Surg. 2020 Jan;46(1):50-60. doi: 10.1097/DSS.0000000000001883.

PMID:
30829771
6.

The complex architecture and epigenomic impact of plant T-DNA insertions.

Jupe F, Rivkin AC, Michael TP, Zander M, Motley ST, Sandoval JP, Slotkin RK, Chen H, Castanon R, Nery JR, Ecker JR.

PLoS Genet. 2019 Jan 18;15(1):e1007819. doi: 10.1371/journal.pgen.1007819. eCollection 2019 Jan.

7.

Aesthetic Treatment Positively Impacts Social Perception: Analysis of Subjects From the HARMONY Study.

Dayan S, Rivkin A, Sykes JM, Teller CF, Weinkle SH, Shumate GT, Gallagher CJ.

Aesthet Surg J. 2019 Nov 13;39(12):1380-1389. doi: 10.1093/asj/sjy239.

PMID:
30239596
8.

Robust single-cell DNA methylome profiling with snmC-seq2.

Luo C, Rivkin A, Zhou J, Sandoval JP, Kurihara L, Lucero J, Castanon R, Nery JR, Pinto-Duarte A, Bui B, Fitzpatrick C, O'Connor C, Ruga S, Van Eden ME, Davis DA, Mash DC, Behrens MM, Ecker JR.

Nat Commun. 2018 Sep 20;9(1):3824. doi: 10.1038/s41467-018-06355-2.

9.

Safety and Effectiveness of Repeat Treatment With VYC-15L for Lip and Perioral Enhancement: Results From a Prospective Multicenter Study.

Rivkin A, Weinkle SH, Hardas B, Weiss RA, Glaser DA, Biesman BS, Schumacher A, Murphy DK.

Aesthet Surg J. 2019 Mar 14;39(4):413-422. doi: 10.1093/asj/sjy019.

10.

Impact of Comprehensive, Minimally Invasive, Multimodal Aesthetic Treatment on Satisfaction With Facial Appearance: The HARMONY Study.

Weinkle SH, Werschler WP, Teller CF, Sykes JM, Shamban A, Rivkin A, Narurkar VA, Kaminer MS, Dayan S, Cohen JL, Gallagher CJ.

Aesthet Surg J. 2018 Apr 6;38(5):540-556. doi: 10.1093/asj/sjx179.

PMID:
29244069
11.

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.

Özdener AE, Rivkin A.

Drug Des Devel Ther. 2017 Sep 26;11:2827-2840. doi: 10.2147/DDDT.S127405. eCollection 2017. Review.

12.

Development of a cyclosporin A derivative with excellent anti-hepatitis C virus potency.

Fu J, Becker C, Cao L, Capparelli M, Denay R, Fujimoto R, Gai Y, Gao Z, Guenat C, Karur S, Kim H, Li W, Li X, Li W, Lochmann T, Lu A, Lu P, Luneau A, Meier N, Mergo W, Ng S, Parker D, Peng Y, Riss B, Rivkin A, Roggo S, Schroeder H, Schuerch F, Simmons RL, Sun F, Sweeney ZK, Tjandra M, Wang M, Wang R, Weiss AH, Wenger N, Wu Q, Xiong X, Xu S, Xu W, Yifru A, Zhao J, Zhou J, Zürcher C, Gallou F.

Bioorg Med Chem. 2018 Feb 15;26(4):957-969. doi: 10.1016/j.bmc.2017.09.008. Epub 2017 Sep 7.

PMID:
28919180
13.

Structural basis for therapeutic inhibition of influenza A polymerase PB2 subunit.

Ma X, Xie L, Wartchow C, Warne R, Xu Y, Rivkin A, Tully D, Shia S, Uehara K, Baldwin DM, Muiru G, Zhong W, Zaror I, Bussiere DE, Leonard VHJ.

Sci Rep. 2017 Aug 24;7(1):9385. doi: 10.1038/s41598-017-09538-x.

14.

Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.

Elwood F, Witter DJ, Piesvaux J, Kraybill B, Bays N, Alpert C, Goldenblatt P, Qu Y, Ivanovska I, Lee HH, Chiu CS, Tang H, Scott ME, Deshmukh SV, Zielstorff M, Byford A, Chakravarthy K, Dorosh L, Rivkin A, Klappenbach J, Pan BS, Kariv I, Dinsmore C, Slipetz D, Dandliker PJ.

J Pharmacol Exp Ther. 2017 May;361(2):229-244. doi: 10.1124/jpet.116.239723. Epub 2017 Feb 13.

PMID:
28193636
15.

Thinking Clinically from the Beginning: Early Introduction of the Pharmacists' Patient Care Process.

Rivkin A.

Am J Pharm Educ. 2016 Dec 25;80(10):164. doi: 10.5688/ajpe8010164.

16.

Malaria Parasites Distribute Subversive Messages across Enemy Lines.

Rivkin A, Ben-Hur S, Regev-Rudzki N.

Trends Parasitol. 2017 Jan;33(1):2-4. doi: 10.1016/j.pt.2016.11.005. Epub 2016 Nov 23.

PMID:
27889370
17.

Highly Modified Cellulose Nanocrystals and Formation of Epoxy-Nanocrystalline Cellulose (CNC) Nanocomposites.

Abraham E, Kam D, Nevo Y, Slattegard R, Rivkin A, Lapidot S, Shoseyov O.

ACS Appl Mater Interfaces. 2016 Oct 19;8(41):28086-28095. doi: 10.1021/acsami.6b09852. Epub 2016 Oct 10.

PMID:
27704756
18.

Volume correction in the aging hand: role of dermal fillers.

Rivkin AZ.

Clin Cosmet Investig Dermatol. 2016 Aug 30;9:225-32. doi: 10.2147/CCID.S92853. eCollection 2016.

19.

Identification and classification of the malaria parasite blood developmental stages, using imaging flow cytometry.

Dekel E, Rivkin A, Heidenreich M, Nadav Y, Ofir-Birin Y, Porat Z, Regev-Rudzki N.

Methods. 2017 Jan 1;112:157-166. doi: 10.1016/j.ymeth.2016.06.021. Epub 2016 Jun 25.

PMID:
27350362
20.

A Comprehensive Approach to Multimodal Facial Aesthetic Treatment: Injection Techniques and Treatment Characteristics From the HARMONY Study.

Narurkar VA, Cohen JL, Dayan S, Kaminer MS, Rivkin A, Shamban A, Sykes JM, Teller CF, Weinkle SH, Werschler WP, Drinkwater A, Pucci ML, Gallagher CJ.

Dermatol Surg. 2016 May;42 Suppl 2:S177-91. doi: 10.1097/DSS.0000000000000743. Erratum in: Dermatol Surg. 2016 Nov;42(11):1311.

PMID:
27128246
21.

Extracellular Matrix Modulation: Optimizing Skin Care and Rejuvenation Procedures.

Widgerow AD, Fabi SG, Palestine RF, Rivkin A, Ortiz A, Bucay VW, Chiu A, Naga L, Emer J, Chasan PE.

J Drugs Dermatol. 2016 Apr;15(4 Suppl):s63-71.

PMID:
27050707
22.

Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.

Rivkin A, Rybalov S.

Pharmacotherapy. 2016 Mar;36(3):300-16. doi: 10.1002/phar.1712. Epub 2016 Mar 11. Review.

PMID:
26971716
23.

Nanocellulose, a tiny fiber with huge applications.

Abitbol T, Rivkin A, Cao Y, Nevo Y, Abraham E, Ben-Shalom T, Lapidot S, Shoseyov O.

Curr Opin Biotechnol. 2016 Jun;39:76-88. doi: 10.1016/j.copbio.2016.01.002. Epub 2016 Feb 28. Review.

PMID:
26930621
24.

Identification and characterization of haemofungin, a novel antifungal compound that inhibits the final step of haem biosynthesis.

Ben Yaakov D, Rivkin A, Mircus G, Albert N, Dietl AM, Kovalerchick D, Carmeli S, Haas H, Kontoyiannis DP, Osherov N.

J Antimicrob Chemother. 2016 Apr;71(4):946-52. doi: 10.1093/jac/dkv446. Epub 2016 Jan 7.

25.

Biophysical and biological characterisation of collagen/resilin-like protein composite fibres.

Sanami M, Shtein Z, Sweeney I, Sorushanova A, Rivkin A, Miraftab M, Shoseyov O, O'Dowd C, Mullen AM, Pandit A, Zeugolis DI.

Biomed Mater. 2015 Nov 6;10(6):065005. doi: 10.1088/1748-6041/10/6/065005.

PMID:
26541078
26.

Potent benzoazepinone γ-secretase modulators with improved bioavailability.

Methot JL, Fischer C, Li C, Rivkin A, Ahearn SP, Brown WC, Kattar S, Kelley E, Mampreian DM, Schell A, Rosenau A, Zhou H, Ball R, Deshmukh SV, Jeliazkova-Mecheva VV, Diaz D, Moy LY, Kenific CM, Moxham C, Shah S, Nuthall H, Szewczak AA, Hill A, Hughes B, Smotrov N, Munoz B, Miller TA, Shearman MS.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3495-500. doi: 10.1016/j.bmcl.2015.06.032. Epub 2015 Jun 15.

PMID:
26142947
27.

Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice.

Kalabalik J, Rattinger GB, Sullivan J, Slugocki M, Carbone A, Rivkin A.

Drugs. 2015 Jun;75(9):979-98. doi: 10.1007/s40265-015-0405-y. Review.

PMID:
25998374
28.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.

Carruthers J, Rivkin A, Donofrio L, Bertucci V, Somogyi C, Lei X, Davis PG, Campo A, Beddingfield FC.

Dermatol Surg. 2015 Jun;41(6):702-11. doi: 10.1097/DSS.0000000000000357.

PMID:
25993609
29.

Long-term effects of onabotulinumtoxinA on facial lines: a 19-year experience of identical twins.

Rivkin A, Binder WJ.

Dermatol Surg. 2015 Jan;41 Suppl 1:S64-6. doi: 10.1097/DSS.0000000000000193. No abstract available.

PMID:
25548847
30.

Perioperative nonopioid agents for pain control in spinal surgery.

Rivkin A, Rivkin MA.

Am J Health Syst Pharm. 2014 Nov 1;71(21):1845-57. doi: 10.2146/ajhp130688.

PMID:
25320134
31.

Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.

Fu J, Tjandra M, Becker C, Bednarczyk D, Capparelli M, Elling R, Hanna I, Fujimoto R, Furegati M, Karur S, Kasprzyk T, Knapp M, Leung K, Li X, Lu P, Mergo W, Miault C, Ng S, Parker D, Peng Y, Roggo S, Rivkin A, Simmons RL, Wang M, Wiedmann B, Weiss AH, Xiao L, Xie L, Xu W, Yifru A, Yang S, Zhou B, Sweeney ZK.

J Med Chem. 2014 Oct 23;57(20):8503-16. doi: 10.1021/jm500862r. Epub 2014 Oct 13.

PMID:
25310383
32.

A prospective study of non-surgical primary rhinoplasty using a polymethylmethacrylate injectable implant.

Rivkin A.

Dermatol Surg. 2014 Mar;40(3):305-13. doi: 10.1111/dsu.12415. Epub 2014 Jan 18.

PMID:
24438233
33.

A quantitative professionalism policy in a community pharmacy introductory pharmacy practice experience.

Shtaynberg J, Rivkin A, Shah B, Rush S.

Am J Pharm Educ. 2013 Dec 16;77(10):217. doi: 10.5688/ajpe7710217.

34.

Verbal final exam in introductory biology yields gains in student content knowledge and longitudinal performance.

Luckie DB, Rivkin AM, Aubry JR, Marengo BJ, Creech LR, Sweeder RD.

CBE Life Sci Educ. 2013 Fall;12(3):515-29. doi: 10.1187/cbe.12-04-0050.

35.

Student preferences regarding teaching methods in a drug-induced diseases and clinical toxicology course.

Rivkin A, Gim S.

Am J Pharm Educ. 2013 Aug 12;77(6):123. doi: 10.5688/ajpe776123.

36.

Less teaching, more learning: 10-yr study supports increasing student learning through less coverage and more inquiry.

Luckie DB, Aubry JR, Marengo BJ, Rivkin AM, Foos LA, Maleszewski JJ.

Adv Physiol Educ. 2012 Dec;36(4):325-35. doi: 10.1152/advan.00017.2012.

37.

The role of vascular endothelial growth factors and fibroblast growth factors in angiogenesis during otitis media.

Husseman J, Palacios SD, Rivkin AZ, Oehl H, Ryan AF.

Audiol Neurootol. 2012;17(3):148-54. doi: 10.1159/000333805. Epub 2011 Nov 19.

38.

A randomized, double-blind, crossover comparison of MK-0929 and placebo in the treatment of adults with ADHD.

Rivkin A, Alexander RC, Knighton J, Hutson PH, Wang XJ, Snavely DB, Rosah T, Watt AP, Reimherr FW, Adler LA.

J Atten Disord. 2012 Nov;16(8):664-74. doi: 10.1177/1087054711423633. Epub 2011 Nov 16.

PMID:
22090395
39.

Recombinant exon-encoded resilins for elastomeric biomaterials.

Qin G, Rivkin A, Lapidot S, Hu X, Preis I, Arinus SB, Dgany O, Shoseyov O, Kaplan DL.

Biomaterials. 2011 Dec;32(35):9231-43. doi: 10.1016/j.biomaterials.2011.06.010. Epub 2011 Sep 29.

40.

Rifaximin: new therapeutic indication and future directions.

Rivkin A, Gim S.

Clin Ther. 2011 Jul;33(7):812-27. doi: 10.1016/j.clinthera.2011.06.007. Epub 2011 Jul 7. Review.

PMID:
21741091
41.

12-Month controlled study in the United States of the safety and efficacy of a permanent 2.5% polyacrylamide hydrogel soft-tissue filler.

Narins RS, Coleman WP 3rd, Rohrich R, Monheit G, Glogau R, Brandt F, Bruce S, Colen L, Dayan S, Jackson I, Maas C, Rivkin A, Sclafani A, Spivak JC.

Dermatol Surg. 2010 Nov;36 Suppl 3:1819-29. doi: 10.1111/j.1524-4725.2010.01736.x.

PMID:
20969659
42.
43.

Detection of ice and organics on an asteroidal surface.

Rivkin AS, Emery JP.

Nature. 2010 Apr 29;464(7293):1322-3. doi: 10.1038/nature09028.

PMID:
20428165
44.

Purine derivatives as potent gamma-secretase modulators.

Rivkin A, Ahearn SP, Chichetti SM, Hamblett CL, Garcia Y, Martinez M, Hubbs JL, Reutershan MH, Daniels MH, Siliphaivanh P, Otte KM, Li C, Rosenau A, Surdi LM, Jung J, Hughes BL, Crispino JL, Nikov GN, Middleton RE, Moxham CM, Szewczak AA, Shah S, Moy LY, Kenific CM, Tanga F, Cruz JC, Andrade P, Angagaw MH, Shomer NH, Miller T, Munoz B, Shearman MS.

Bioorg Med Chem Lett. 2010 Apr 1;20(7):2279-82. doi: 10.1016/j.bmcl.2010.02.008. Epub 2010 Feb 6.

PMID:
20207146
45.

Earth encounters as the origin of fresh surfaces on near-Earth asteroids.

Binzel RP, Morbidelli A, Merouane S, Demeo FE, Birlan M, Vernazza P, Thomas CA, Rivkin AS, Bus SJ, Tokunaga AT.

Nature. 2010 Jan 21;463(7279):331-4. doi: 10.1038/nature08709.

PMID:
20090748
46.

Piperazinyl pyrimidine derivatives as potent gamma-secretase modulators.

Rivkin A, Ahearn SP, Chichetti SM, Kim YR, Li C, Rosenau A, Kattar SD, Jung J, Shah S, Hughes BL, Crispino JL, Middleton RE, Szewczak AA, Munoz B, Shearman MS.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1269-71. doi: 10.1016/j.bmcl.2009.11.101. Epub 2009 Nov 23.

PMID:
20022243
47.

The shape and surface variation of 2 Pallas from the Hubble Space Telescope.

Schmidt BE, Thomas PC, Bauer JM, Li JY, McFadden LA, Mutchler MJ, Radcliffe SC, Rivkin AS, Russell CT, Parker JW, Stern SA.

Science. 2009 Oct 9;326(5950):275-8. doi: 10.1126/science.1177734.

48.

Certolizumab pegol for the management of Crohn's disease in adults.

Rivkin A.

Clin Ther. 2009 Jun;31(6):1158-76. doi: 10.1016/j.clinthera.2009.06.015. Review.

PMID:
19695385
49.

New fillers under consideration: what is the future of injectable aesthetics?

Rivkin A.

Facial Plast Surg. 2009 May;25(2):120-3. doi: 10.1055/s-0029-1220652. Epub 2009 May 4.

PMID:
19415580
50.

The history of injectable facial fillers.

Kontis TC, Rivkin A.

Facial Plast Surg. 2009 May;25(2):67-72. doi: 10.1055/s-0029-1220645. Epub 2009 May 4.

PMID:
19415573

Supplemental Content

Loading ...
Support Center